The Central Social Insurance Medical Council, a key Japanese reimbursement policy panel better known as Chuikyo, approved an outline of…
REGULATORY
Japan Moves LLP Payment Hike toward Political Call, Eyes 1/2 or Higher
Japan is heading toward raising extra patient charges for long-listed products (LLPs) after the health ministry proposed a hike to at least one-half of the price gap from generics at a panel meeting on December 17. The specific ratio will…
To read the full story
Related Article
- Japan Ministers Agree to Scrap “Spillover” Rule, Plan Wider CEA Price Cuts
December 25, 2025
- Panel Backs Extra Charges for OTC-Like Drugs While Keeping Coverage, but Design Details Still Divisive
November 28, 2025
- Patient Groups Push Back against Delisting OTC-Like Drugs; Panel Leans Toward Higher Copays
November 21, 2025
- Chuikyo Split over Higher Copays under LLP Scheme; Payer Push Meets Provider Caution
November 17, 2025
- MHLW Weighs Higher Copay Ratios for LLPs; 1/2 to Full Gap on the Table
November 7, 2025
REGULATORY
- MHLW Pharma Director Says Uniform Drug Price Hike “Not Realistic,” Targeted Support Preferred
January 9, 2026
- MHLW Issues Guidance on Revised PMD Act Ahead of May Enforcement
January 6, 2026
- MHLW Sets Up Drug Discovery Support Office Ahead of New Fund Launch
January 6, 2026
- Ex-JPMA President Ueno Takes on New AMED Advisor Role
January 6, 2026
- Cabinet OKs FY2026 Tax Reform Package, Creates Strategic Tech R&D Credit
January 5, 2026
As many as 47 new drug candidates are expected to win approval or secure NHI price listing in Japan in…
Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…